Almirall's Lebrikizumab Shows Sustained Efficacy Over Five Years in Atopic Dermatitis Study
Event summary
- Almirall's Phase 3b ADlong study shows lebrikizumab maintains efficacy in moderate-to-severe atopic dermatitis patients for up to five years.
- Key efficacy metrics at week 108: 92.9% EASI-75 response, 73.8% EASI-90 response, 66.7% IGA 0/1 response, and 78.0% Pruritus NRS ≤4 response.
- Long-term safety profile consistent with previous studies, with no new safety signals identified.
- Results presented at the 35th EADV Congress in Vienna, Austria, on October 1, 2026.
The big picture
Almirall's long-term data for lebrikizumab reinforces its commitment to medical dermatology, particularly in addressing the chronic nature of atopic dermatitis. The sustained efficacy over five years positions the company to compete with established players like Eli Lilly, which holds rights to lebrikizumab outside Europe. This strategic advantage could enhance Almirall's market position, especially as it expands its dermatology portfolio.
What we're watching
- Market Differentiation
- Whether lebrikizumab's sustained efficacy can position Almirall competitively against other IL-13 inhibitors in the atopic dermatitis market.
- Regulatory Expansion
- The pace at which Almirall can secure additional regulatory approvals for lebrikizumab in new geographies or indications.
- Commercial Strategy
- How Almirall leverages these long-term data to drive adoption and market penetration of lebrikizumab in Europe.